ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2025
Comparison of Latest Generation Intra- and Supra-Annular Self-Expanding Transcatheter Heart Valves for Aortic Valve-in-Valve Procedures.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundValve-in-valve (ViV) procedures are an established therapy. Self-expanding (SE) supra-annular transcatheter heart valves (THV) achieve superior hemodynamics compared to balloon-expandable (BE) intra-annular THV, but influence of stent design versus valve position remains unclear.
aimsThis study compares SE intra- and supra-annular THV for aortic ViV procedures to further elucidate this topic.
methodsFrom 05/2022 to 11/2023, 10 patients underwent ViV procedures with the SE intra-annular Navitor valve. A control group of 22 patients treated with the SE supra-annular Evolut R/PRO valve during the same period was retrieved from our database. Data were retrospectively analyzed according to updated valve academic research consortium (VARC) 3 definitions. A subgroup analysis matched patients for true internal diameter (ID) and body mass index (BMI).
resultsPostprocedural transvalvular gradients were similar between groups. No differences in rates of significant paravalvular leakage (PVL) were seen (p = 0.131). No all-cause mortality occurred in either group. Device success (study group, Navitor: 70 [7] vs. control group, Evolut: 90.1 [20]; p = 0.293), early safety (90 [9] vs. 86.4 [19]; p = 1.000), permanent pacemaker implantation (PPI) (0 [0] vs. 9.1 [2]; p = 1.000), and stroke (0 [0] vs. 4.5 [1]; p = 1.000) were similar between groups. Procedure time was shorter for the study group (65.8 ± 27.9 min vs. 145.7 ± 51.3 min; p < 0.001). After matching for True ID and BMI these results persisted.
conclusionIntra- and supra-annular THV showed similar clinical and hemodynamic outcomes in aortic ViV procedures. These findings highlight the applicability of SE intra-annular THV for aortic ViV procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.